Teva Prices €1.5B Euro Senior Notes, Completing Multi-Tranche Refinancing
TEVA has more than doubled off its 52-week low of $18.21.
Summary
Teva priced €1.5 billion in Euro senior notes across two tranches, finalizing the terms of its multi-currency refinancing alongside the $3.2 billion USD offering priced the same day.
Key Events · Financing and Capital Events · TEVA
-
Euro Notes Priced
Teva priced €1.0B 4.250% senior notes due 2033 at 98.756% (yield 4.479%) and €500M 4.625% senior notes due 2036 at 98.327% (yield 4.840%).
-
Refinancing Economics
The Euro notes carry investment-grade ratings (Baa3/BBB-/BBB-) and spreads of +121.7bps and +140.1bps over German bunds, with a 0.450% underwriting discount on both tranches.
-
Liability Management Context
This completes the multi-tranche offering alongside $3.2B in USD notes priced the same day, funding the conditional redemption of higher-coupon legacy debt including the 8.125% USD Sustainability-linked Notes due 2031.
-
Settlement and Listing
Settlement is expected September 16, 2026 (T+5), with the Euro notes listed on Euronext Dublin / Global Exchange Market.
Analysis · TEVA · Life Sciences
Teva finalized pricing on €1.5 billion of Euro-denominated senior notes, completing the multi-tranche refinancing that began with the $3.2 billion USD tranches priced the same day. The Euro notes carry investment-grade ratings (Baa3/BBB-/BBB-) and yields of 4.479% and 4.840%, with spreads of 121.7 and 140.1 basis points over German bunds. This is part of a larger liability management exercise tied to the conditional redemption of higher-coupon legacy debt, including the 8.125% USD Sustainability-linked Notes due 2031. The combined offering extends Teva's maturity profile and reduces interest expense, though it adds roughly €1.5 billion in new debt principal.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.2% of the 2009 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TEVA was trading at $36.72 on NYSE in the Life Sciences sector, with a market capitalization of approximately $42.9B. The 52-week trading range was $18.21 to $38.37. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.